AbbVie Immunology Deal History & Licensing Activity
AbbVie Immunology is a large pharma headquartered in US. Over the past three years, AbbVie Immunology has been involved in 13 licensing and acquisition transactions, with a primary focus on Other (8 deals). The company currently has 50 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
7
Active Trials
50
Top Modality
Other
Focus Area
Hematological Malignancies
AbbVie Immunology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving AbbVie Immunology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| BI 655066 | AbbVie | Other | Phase 3 | license | Mar 2026 |
| BI 655064 | AbbVie | Other | Phase 1 | license | Mar 2026 |
| trispecific T-cell engager | AbbVie | Bispecific Antibodies | Phase 1 | option | Jun 2025 |
AbbVie Immunology Pipeline Focus
Therapeutic areas and modalities where AbbVie Immunology is most active based on deal history and clinical trial data.
Therapeutic Areas
AbbVie Immunology Strategic Signals
Key indicators of AbbVie Immunology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
AbbVie Immunology Clinical Pipeline
AbbVie Immunology has 50 active clinical trials across 6 development phases.
3
Phase 4
1
Not Applicable
8
Unknown
21
Phase 1
14
Phase 2
3
Phase 3
See How Your Asset Matches AbbVie Immunology's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About AbbVie Immunology Licensing & Deal Activity
AbbVie Immunology is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 13 deals over the past three years, AbbVie Immunology ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AbbVie Immunology include Hematological Malignancies (8 deals and trials), Option Deals (6 deals and trials), CNS Disorders (6 deals and trials), and Solid Tumors (6 deals and trials). In terms of modality, AbbVie Immunology has shown particular interest in other, bispecific antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AbbVie Immunology and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against AbbVie Immunology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.